Ovarian cancer remains the deadliest gynecological malignancy worldwide, partly due to its high rates of relapse and resistance to conventional therapies. While prior knowledge underscored the role of the immune system in modulating patient outcomes, there was a profound gap in understanding how the immune microenvironment transforms as the cancer returns. This research directly addresses that knowledge deficit by systematically categorizing tumors based on their immune cell infiltration, thereby revealing critical associations between immune phenotypes, genomic features, and therapeutic response.

Central to this study is the novel immune classification system developed by the Ludwig Lausanne team, which analyzed nearly 700 tumor samples from five separate clinical cohorts. Utilizing digital pathology and immunohistochemical techniques focused on the presence of CD8+ T lymphocytes—key effectors in anti-tumor immunity—the researchers delineated four distinct immunologic subtypes of ovarian tumors. Tumors densely infiltrated by T cells were labeled as “purely inflamed,” whereas those with moderate infiltration earned the “mixed-inflamed” marker. Tumors exhibiting T cells only at their edges were designated “excluded,” and those lacking appreciable T cells altogether were termed “desert” tumors.

These immunologic designations proved to be robust predictors of patient survival outcomes. Patients harboring either purely inflamed or mixed-inflamed tumors exhibited significantly prolonged survival compared to those with excluded or desert phenotypes. Importantly, the study uncovered a strong link between tumors harboring mutations in DNA repair genes—most notably BRCA1 mutations—and the inflamed immune microenvironment. Such genetic defects appear to foster enhanced immunogenicity, thereby coupling DNA repair deficiency with favorable chemotherapy responses and extended patient survival.

But the immune complexity of ovarian tumors extends beyond T lymphocyte populations. Myeloid cells, including macrophages and dendritic cells, also occupy pivotal niches within the tumor microenvironment and influence immune dynamics. Macrophages can polarize toward states that either support anti-tumor immunity or suppress it, while dendritic cells orchestrate the activation and priming of T cells. The researchers demonstrated that upon relapse, tumors proficient in DNA repair tend to recruit immunosuppressive macrophages characterized by the expression of lipid metabolism-related proteins ApoE and Trem2. These macrophages contribute to an environment hostile to effective immune clearance and correlate with more resistant tumor phenotypes.

A key translational discovery from this research is the therapeutic potential of targeting Trem2-positive macrophages. Using mouse models, the team showed that employing an antibody inhibitor against Trem2 boosted chemotherapy response and delayed tumor recurrence, suggesting a promising new avenue for patients with tumors that fall into the immunologically “desert” category.

Conversely, tumors classified as purely inflamed and deficient in DNA repair maintain complex networks of TILs and dendritic cells that foster sustained anti-tumor immunity. These immune niches, resilient even after disease recurrence, are further supported by the recruitment of macrophages with anti-tumor functionality, highlighting the interdependence of different immune cell types in maintaining tumor control.

However, even these seemingly immune-favorable tumors are not impervious to immune evasion mechanisms. The study revealed that cancer cells in inflamed, DNA repair-deficient tumors activate a COX enzyme-driven molecular pathway upon treatment with chemotherapy and the PARP inhibitor olaparib—a drug clinically employed for BRCA-mutated ovarian cancer. This pathway elevates the secretion of prostaglandin E2 (PGE2), a lipid mediator that impairs the survival and functionality of tumor-infiltrating lymphocytes by inducing their functional exhaustion and apoptosis.

Importantly, the research team demonstrated that supplementing standard chemotherapy and olaparib with COX inhibitors in murine models significantly extended survival by counteracting PGE2-mediated immunosuppression. When combined further with checkpoint blockade immunotherapy—agents designed to reinvigorate exhausted T cells—the survival benefit was amplified, effectively doubling survival time in these preclinical models.

These findings point to a future in which ovarian cancer treatment is tailored not only on the basis of tumor genetics but also by the precise immune composition of the tumor microenvironment. Patients with inflamed, DNA repair-deficient tumors emerge as ideal candidates for combination immunotherapy trials, while those whose tumors exhibit immunosuppressive myeloid infiltration may gain clinical benefit from emerging therapies that inhibit immune checkpoints and myeloid regulators such as Trem2.

The study underscores a paradigm shift toward integrated therapeutic strategies that simultaneously target malignant cells and the immune components enabling immune evasion. By illuminating the interplay between tumor genomics and the immune microenvironment across the course of disease progression, the findings chart a course toward improved personalization of ovarian cancer therapy, with the potential to significantly alter patient outcomes.

This research was supported by the Myeloid Cells in Cancer Initiative of the Ludwig Institute for Cancer Research, the U.S. Department of Defense, and Hoffmann-La Roche AG, emphasizing the collaborative and multidisciplinary effort required to tackle the complexities of cancer immunology.

Subject of Research: Immune classification and therapeutic targeting of ovarian cancer relapse

Article Title: Immunologic evolution of ovarian tumors defines therapeutic vulnerabilities at relapse

News Publication Date: July 31, 2025

Web References:
– https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00276-4
– https://www.ludwigcancerresearch.org/ludwig-link/december-2024/a-ludwig-lausanne-collaboration-takes-aim-at-myeloid-cells-in-cancer/
– https://www.ludwigcancerresearch.org/news-releases/ludwig-cancer-research-study-identifies-cellular-interactions-essential-to-the-immune-attack-on-ovarian-tumors/
– https://www.ludwigcancerresearch.org/news-releases/immune-networks-in-tumors-prime-responses-to-a-personalized-immunotherapy/

Image Credits: Ludwig Cancer Research

Keywords: ovarian cancer, tumor microenvironment, immunology, immunotherapy, cancer relapse, DNA repair deficiency, T lymphocytes, macrophages, Trem2, COX pathway, PGE2, checkpoint blockade

Tertiary lymphoid structures represent specialized immune cell aggregates that develop ectopically within tumor microenvironments. These formations, comprising T cells, B cells, and dendritic cells, emerge in response to chronic inflammation or neoplastic progression. TLS have been strongly correlated with enhanced immune infiltration and favorable patient outcomes across multiple cancer types, yet their integration into routine pathology workflows remains limited due to detection challenges. The ECOG-ACRIN researchers’ AI-enhanced approach seeks to surmount these hurdles by automating TLS detection through sophisticated image analysis.

The team’s investigation retrospectively analyzed an extensive cohort of 376 patients diagnosed with advanced, high-risk melanoma. By integrating digitized hematoxylin and eosin (H&E)-stained histologic slides with corresponding RNA sequencing datasets, the researchers established a definitive link between TLS presence and markedly improved overall survival. Derived from participants in the landmark E1609 clinical trial—which evaluated immune checkpoint inhibitors and cytokine therapies—this study leverages a robust dataset, positioning it to inform future prognostication and therapeutic stratification efforts.

Quantitative analysis within this cohort revealed TLS in approximately 55% of cases, with significant survival benefits observed in patients harboring TLS compared to those without. Specifically, five-year overall survival rates were 36.23% in TLS-positive patients, contrasting with 29.59% in the TLS-negative group. Intriguingly, patients exhibiting multiple TLS demonstrated an even greater survival advantage, underscoring the prognostic relevance of TLS density alongside presence. Additional stratification highlighted survival variability based on established clinical parameters such as AJCC tumor stage, patient age, sex, therapeutic modality, and tumor ulceration status.

Central to these advancements is the deployment of HookNet-TLS, an innovative open-source deep learning algorithm explicitly designed for automated detection of TLS and germinal centers within digitized histological images. Originally developed for bioimage analysis, HookNet leverages convolutional neural network architectures to perform end-to-end segmentation and classification of complex tissue structures at high resolution. After initial application demonstrated promising outcomes, the researchers undertook model refinement to enhance predictive accuracy, thereby enabling robust quantification of TLS and associated germinal centers.

Complementing HookNet, the investigators incorporated feature extraction capabilities from the Gigapth Whole-Slide Foundation Model—an emerging framework optimized for digital pathology. This model facilitates enhanced visualization and analysis of H&E image tiles through the application of principal component analysis (PCA), effectively capturing essential morphological variations that contribute to TLS identification. Early PCA visualizations generated via Gigapth underscore its potential to augment detection fidelity, though ongoing fine-tuning and validation remain underway.

The implications of integrating such AI-driven tools into routine clinical workflows are profound. By automating the evaluation of TLS using low-cost, widely accessible H&E-stained samples, this approach promises to standardize assessments that have previously been subjective and resource-intensive. Moreover, the enhanced sensitivity and specificity in TLS detection could enable more accurate prognostication within the AJCC staging framework, ultimately informing personalized immunotherapy decisions and improving clinical outcomes for high-risk melanoma patients.

This research initiative, supported by funding from the National Cancer Institute, exemplifies the transformative potential of synergizing biomedical imaging, machine learning, and molecular oncology. The ability to rapidly and reproducibly quantify critical immune microenvironment components paves the way for integrating biomarkers like TLS into established diagnostic paradigms and therapeutic decision-making algorithms.

As highlighted by Dr. Ahmad A. Tarhini, lead investigator and professor at the Moffitt Cancer Center, “Our work showcases how openly accessible AI tools can revolutionize the prediction of survival and immunotherapy response by facilitating detailed immune structure analysis—ushering in a new era of precision oncology.” Co-investigator Dr. Xuefeng Wang emphasized the promise of foundation models like Gigapth in refining such analyses, pointing to ongoing developments that will enhance the robustness and applicability of these methods in broader clinical contexts.

The ability to detect TLS efficiently and accurately could reshape clinical conversations between physicians and patients, particularly regarding the potential benefits of immunotherapy in melanoma. As these AI methodologies mature, they hold promise not just for oncology but also for other immune-related diseases where tertiary lymphoid structures may play pivotal roles.

Tertiary lymphoid structures, by virtue of their composition and spatial organization, represent dynamic hubs of antitumor immune activity. Their detection and quantification have historically required expert pathologists to identify subtle histological features—a challenge complicated by interobserver variability and resource constraints. The successful deployment of AI algorithms like HookNet-TLS, which automate these tasks with high precision, addresses critical gaps in workflow efficiency and diagnostic standardization.

Furthermore, the public release of HookNet’s source code on platforms such as Grand Challenge fosters transparency and collaboration across the biomedical imaging and AI communities. This open-source ethos accelerates innovation, enabling researchers worldwide to adapt and refine algorithms for localized datasets, diverse cancer types, and extended biomedical applications.

The advancements demonstrated in this work are poised to be presented at the upcoming American Association for Cancer Research 2025 Annual Meeting in Chicago, where further insights into model performance and clinical applicability will be shared. The anticipated dissemination of these results will likely catalyze interest and investment in AI-facilitated pathology, heralding a paradigm shift in how immune biomarkers inform oncologic care.

By leveraging sophisticated AI frameworks to harness existing digital pathology resources, the ECOG-ACRIN team has unlocked new dimensions in melanoma prognostication, showcasing a scalable path forward for integrating machine learning into precision medicine.

Subject of Research: Artificial intelligence-driven detection of tertiary lymphoid structures in advanced melanoma for improved survival prediction

Article Title: Not explicitly provided in the content

News Publication Date: Not explicitly stated

Web References:

• ECOG-ACRIN Cancer Research Group: www.ecog-acrin.org
• Grand Challenge platform: https://grand-challenge.org/
• HookNet-TLS algorithm: https://grand-challenge.org/algorithms/hooknet-tls/
• AACR 2025 Annual Meeting (implied)

References:

• Tarhini A. J Clin Oncol. February 2020
• Rijthoven M. Med Image Anal. February 2021
• Rijthoven M. Communications Nature. January 2024

Image Credits: Ahmad A. Tarhini, et al

Keywords: Artificial intelligence, Melanoma, Image analysis, Biomarkers, Skin cancer, RNA sequencing